Metraipolis › archive › dc_f2a6125ffbe6

Optimizing anti-TNF therapy in Behçet's disease: the role of therapeutic drug monitoring — Europe PMC PMID:42609342

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42609342
DOI
10.3389/fimmu.2026.1930666
License (as archived)
solo-consultazione
Archived
2026-10-08T07:00:56.117Z
SHA-256 of the archived text
7e5776cac4a01ed49eb747457cd0befbaadd3182aa629f2433ad6d9ee414ffa3
Stable URL of this page
https://metraipolis.com/documento/dc_f2a6125ffbe6

How to cite

Optimizing anti-TNF therapy in Behçet's disease: the role of therapeutic drug monitoring — Europe PMC PMID:42609342 — Europe PMC (en), https://europepmc.org/article/MED/42609342 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f2a6125ffbe6 (Metraipolis archive dc_f2a6125ffbe6, sha256 7e5776cac4a01ed49eb747457cd0befbaadd3182aa629f2433ad6d9ee414ffa3)
BibTeX
@misc{dcf2a6125ffbe6,
  title = {Optimizing anti-TNF therapy in Behçet's disease: the role of therapeutic drug monitoring — Europe PMC PMID:42609342},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42609342},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f2a6125ffbe6; sha256 7e5776cac4a01ed49eb747457cd0befbaadd3182aa629f2433ad6d9ee414ffa3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42609342. Agents can read the archived copy with the MCP tool read_document.